BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 23888342)

  • 1. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
    Bacevičienė R; Valonytė L; Ceponis J
    Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
    Glintborg D; Vaegter HB; Christensen LL; Bendix E; Graven-Nielsen T; Andersen PG; Andersen M
    Eur J Endocrinol; 2020 Jun; 182(6):539-548. PubMed ID: 32213659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
    Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
    Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy.
    Rosen RC; Seftel AD; Ruff DD; Muram D
    Am J Mens Health; 2018 May; 12(3):567-574. PubMed ID: 26819183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
    Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
    BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction, insulin resistance and inflammation in congenital hypogonadism, and the effect of testosterone replacement.
    Sonmez A; Haymana C; Aydogdu A; Tapan S; Basaran Y; Meric C; Baskoy K; Dinc M; Yazici M; Taslipinar A; Barcin C; Yilmaz MI; Bolu E; Azal O
    Endocr J; 2015; 62(7):605-13. PubMed ID: 25924666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
    Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
    Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
    Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
    Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism.
    Aydogan U; Eroglu A; Akbulut H; Yildiz Y; Gok DE; Sonmez A; Aydin T; Bolu E; Saglam K
    Endocr J; 2012; 59(4):321-7. PubMed ID: 22277727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
    Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
    Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central body fat changes in men affected by post-surgical hypogonadotropic hypogonadism undergoing testosterone replacement therapy are modulated by androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Buldreghini E; Lenzi A; Balercia G
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):908-13. PubMed ID: 24787905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.